EP4288057A1 — Combination therapy for treating abnormal cell growth
Assigned to Verastem Inc · Expires 2023-12-13 · 2y expired
What this patent protects
The present invention relates to methods, compositions, and oral dosage forms of a SHP2 inhibitor, a SOS1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a du…
USPTO Abstract
The present invention relates to methods, compositions, and oral dosage forms of a SHP2 inhibitor, a SOS1 inhibitor, an ERK1/2 inhibitor, a CDK4/6 inhibitor, an AKT inhibitor, an mTOR inhibitor, a pan-HER inhibitor, or an EGFR inhibitor in combination with a MEK inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.